A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: The antiemetic effect of ondansetron

被引:47
作者
Cox, EH
Veyrat-Follet, C
Beal, SL
Fuseau, E
Kenkare, S
Sheiner, LB
机构
[1] Univ Calif San Francisco, Sch Med, Dept Lab Med, San Francisco, CA 94143 USA
[2] Pharsight Corp, Leiden, Netherlands
[3] Rhone Poulenc Rorer, Pharmacokinet & Drug Metab, Antony, France
[4] GloboMax Europe, Slough, Berks, England
[5] Genentech Inc, Pharmacokinet Metab, S San Francisco, CA 94080 USA
[6] Univ Calif San Francisco, Sch Pharm, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1999年 / 27卷 / 06期
关键词
PK/PD; ondansetron; time-to-event; random effects; frailty models; hierarchical models; emesis; time-dependent hazard; repeated-measures; model diagnostics; model evaluation;
D O I
10.1023/A:1020930626404
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT3 antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a "posterior predictive check" wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4 +/- 0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5 +/- 0.2 hr(-1).
引用
收藏
页码:625 / 644
页数:20
相关论文
共 24 条
  • [1] [Anonymous], 1994, Modeling Survival Data in Medical Research
  • [2] [Anonymous], 1996, Survival analysis with long-term survivors
  • [3] PLASMA-CONCENTRATIONS OF ALFENTANIL REQUIRED TO SUPPLEMENT NITROUS-OXIDE ANESTHESIA FOR GENERAL-SURGERY
    AUSEMS, ME
    HUG, CC
    STANSKI, DR
    BURM, AGL
    [J]. ANESTHESIOLOGY, 1986, 65 (04) : 362 - 373
  • [4] BELA SL, 1992, NONMEM USERS GUIDES
  • [5] Efficacy measures: Surrogates or clinical outcomes?
    Blue, JW
    Colburn, WA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (09) : 767 - 770
  • [6] DETERMINATION OF ONDANSETRON IN PLASMA AND ITS PHARMACOKINETICS IN THE YOUNG AND ELDERLY
    COLTHUP, PV
    FELGATE, CC
    PALMER, JL
    SCULLY, NL
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (09) : 868 - 871
  • [7] A GENERAL DEFINITION OF RESIDUALS
    COX, DR
    SNELL, EJ
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1968, 30 (02) : 248 - &
  • [8] PHARMACOKINETIC PHARMACODYNAMIC MODELING OF CNS DRUG EFFECTS - AN OVERVIEW
    DINGEMANSE, J
    DANHOF, M
    BREIMER, DD
    [J]. PHARMACOLOGY & THERAPEUTICS, 1988, 38 (01) : 1 - 52
  • [9] Fleming T. R., 1991, COUNTING PROCESSES S
  • [10] Gelman A, 1996, STAT SINICA, V6, P733